Melanoma in Minutes: Evidence-Driven Care for Improved Patient Outcomes Module 2
In this concluding module, Michael A. Davies, MD, PhD, University of Texas, MD Anderson Cancer Center, addresses the critical challenges of managing treatment-associated toxicities in the era of advanced melanoma therapies. Discover practical strategies for handling immune-related adverse events, implementing comprehensive supportive care, and optimizing patient education. This podcast is critical for oncology professionals seeking to balance therapeutic efficacy with quality of life for patients receiving cutting-edge immunotherapy and targeted treatments.
Click here to go back and listen to module 1 of this podcast series: [link]
Click here to claim your CME/NCPD credit: [link]
-------- Â
20:58
Melanoma in Minutes: Evidence-Driven Care for Improved Patient Outcomes - Module 1
Join melanoma authority Michael A. Davies, MD, PhD, University of Texas, MD Anderson Cancer Center, as he navigates the latest breakthroughs in immunotherapy and targeted treatments transforming outcomes for patients with melanoma. Discover how predictive biomarkers, strategic combination therapies, and personalized treatment sequencing are revolutionizing care across neoadjuvant, adjuvant, and metastatic settings. This podcast is essential listening for oncology professionals seeking evidence-based approaches to combat this challenging disease affecting over 100,000 Americans annually.
Click here to listen to module 2 of this podcast series: [link]
Click here to claim your CME/NCPD credit: [link]
-------- Â
49:42
Harnessing AI for Early Lung Cancer Detection: Qure.ai’s Innovations and Impact
In this episode of the Exploring AI in Oncology podcast, Waqas Haque, MD, MPH, a Hematology/Oncology Fellow at the University of Chicago, speaks with Samir Shah, MD, MMM, FACR, the Chief Medical Officer at Qure.ai. Their discussion explores how Qure.ai’s innovative AI solutions are addressing critical gaps in lung cancer screening and improving early detection through advanced image analysis and clinical data integration.
-------- Â
19:01
Mastering Systemic Mastocytosis: From Early Detection to Tailored Treatment Strategies - Module 2
Tune in to Module 2 of our podcast series as Dr. Mariana Castells, Director of the Mastocytosis Center at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School, explores strategies for developing personalized management plans for patients with systemic mastocytosis (SM). This episode covers the latest advancements in treatment, including tyrosine kinase inhibitors (TKIs), supportive care interventions, and practical approaches to tailoring therapies based on disease subtype and symptom burden. Listen now to stay up to date on best practices for improving patient outcomes and quality of life—and don’t forget to claim your credit after the episode!
Click here to claim credit for this activity: bit.ly/43VoFNP
-------- Â
27:41
Mastering Systemic Mastocytosis: From Early Detection to Tailored Treatment Strategies - Module 1
Join Dr. Mariana Castells, Director of the Mastocytosis Center at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School, in Module 1 of this podcast series as she explores the challenges of diagnosing systemic mastocytosis (SM), a rare and often under recognized mast cell disease.
In this episode, Dr. Castells discusses the wide range of SM symptoms—including anaphylaxis, cutaneous, gastrointestinal, neuropsychiatric, and musculoskeletal manifestations—and offers essential guidance on recognizing the signs, confirming the diagnosis, and improving patient outcomes through early intervention.
Listen now to enhance your clinical knowledge and be sure to claim your credit after the episode!
Click on the link to claim your credit now: bit.ly/3Y3ivHM
Click here to continue listening to Module 2 of this podcast series: bit.ly/43VoFNP
The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.